drugset / Trial / NCT05049850
A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess whether imlifidase in combination with bortezomib, belatacept, rituximab and IVIg can suppress donor specific antibodies (DSA) and the occurrence of antibody-mediated rejection (AMR) in highly sensitized patients with chronic kidney disease with a positive crossmatch towards their living donor during a period of 3 months from transplantation.
Timeline
- Start
- 2022-12-16
- Primary completion
- 2024-02-05
- Completion
- 2024-05-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imlifidase | Protein / enzyme biologic | 0.25 mg/kg | Intravenous |
Indications
No indication recorded.